Also known as: AACR
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
Yale Cancer Center experts presented research at the 2026 AACR Annual Meeting in San Diego, including patient-centered trials, pathology methods and head and neck cancer studies. The meeting also included a plenary presentation, a pathology award and an AACR Trailblazer Cancer Research Grant.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Rznomics said it will present interim AACR results for liver cancer candidate RZ-001 from a U.S. trial in patients with hepatocellular carcinoma. Tumor-shrinking responses were observed, and about 23% experienced complete disappearance of cancer cells.
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
Korean biotech firms will present next-generation cancer therapies at the AACR meeting, including CAR-T platforms for solid tumors, mRNA-based treatments, radiopharmaceuticals, and bispecific antibody ADCs. Companies like AbClon, Verismo Therapeutics, Hanmi Pharmaceutical, and SK Biopharmaceuticals will showcase their latest research.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07341503 |
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients |
RECRUITING | |
| NCT07290985 |
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas |
NOT_YET_RECRUITING | PHASE2 |
| NCT06298734 |
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial |
RECRUITING | NA |
| NCT04691297 |
Digitally Enhanced Smoking Cessation for High Risk Smokers |
ACTIVE_NOT_RECRUITING | NA |
| NCT04400903 |
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer |
TERMINATED | |
| NCT04177810 |
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer |
COMPLETED | PHASE2 |
| NCT04005690 |
Targeted Pathway Inhibition in Patients With Pancreatic Cancer |
RECRUITING | EARLY_PHASE1 |
| NCT03520790 |
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer |
TERMINATED | PHASE1 |
| NCT02432001 |
Radiologically Guided Biopsies of mCRPC |
COMPLETED | |
| NCT02243371 |
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab |
COMPLETED | PHASE2 |
